Report Detail

Pharma & Healthcare 2018-2023 Global Parkinsons Disease Drugs Consumption Market Report

  • RnM2417850
  • |
  • 14 September, 2018
  • |
  • Global
  • |
  • 164 pages
  • |
  • LPI(LP Information)
  • |
  • Pharma & Healthcare

2018-2023 Global Parkinsons Disease Drugs Consumption Market Report

Table of Contents

    2018-2023 Global Parkinsons Disease Drugs Consumption Market Report

      1 Scope of the Report

      • 1.1 Market Introduction
      • 1.2 Research Objectives
      • 1.3 Years Considered
      • 1.4 Market Research Methodology
      • 1.5 Economic Indicators
      • 1.6 Currency Considered

      2 Executive Summary

      • 2.1 World Market Overview
        • 2.1.1 Global Parkinsons Disease Drugs Consumption 2013-2023
        • 2.1.2 Parkinsons Disease Drugs Consumption CAGR by Region
      • 2.2 Parkinsons Disease Drugs Segment by Type
        • 2.2.1 Clinical
        • 2.2.2 Experiment
      • 2.3 Parkinsons Disease Drugs Consumption by Type
        • 2.3.1 Global Parkinsons Disease Drugs Consumption Market Share by Type (2013-2018)
        • 2.3.2 Global Parkinsons Disease Drugs Revenue and Market Share by Type (2013-2018)
        • 2.3.3 Global Parkinsons Disease Drugs Sale Price by Type (2013-2018)
      • 2.4 Parkinsons Disease Drugs Segment by Application
        • 2.4.1 Treament
        • 2.4.2 Prevention
      • 2.5 Parkinsons Disease Drugs Consumption by Application
        • 2.5.1 Global Parkinsons Disease Drugs Consumption Market Share by Application (2013-2018)
        • 2.5.2 Global Parkinsons Disease Drugs Value and Market Share by Application (2013-2018)
        • 2.5.3 Global Parkinsons Disease Drugs Sale Price by Application (2013-2018)

      3 Global Parkinsons Disease Drugs by Players

      • 3.1 Global Parkinsons Disease Drugs Sales Market Share by Players
        • 3.1.1 Global Parkinsons Disease Drugs Sales by Players (2016-2018)
        • 3.1.2 Global Parkinsons Disease Drugs Sales Market Share by Players (2016-2018)
      • 3.2 Global Parkinsons Disease Drugs Revenue Market Share by Players
        • 3.2.1 Global Parkinsons Disease Drugs Revenue by Players (2016-2018)
        • 3.2.2 Global Parkinsons Disease Drugs Revenue Market Share by Players (2016-2018)
      • 3.3 Global Parkinsons Disease Drugs Sale Price by Players
      • 3.4 Global Parkinsons Disease Drugs Manufacturing Base Distribution, Sales Area, Product Types by Players
        • 3.4.1 Global Parkinsons Disease Drugs Manufacturing Base Distribution and Sales Area by Players
        • 3.4.2 Players Parkinsons Disease Drugs Products Offered
      • 3.5 Market Concentration Rate Analysis
        • 3.5.1 Competition Landscape Analysis
        • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
      • 3.6 New Products and Potential Entrants
      • 3.7 Mergers & Acquisitions, Expansion

      4 Parkinsons Disease Drugs by Regions

      • 4.1 Parkinsons Disease Drugs by Regions
        • 4.1.1 Global Parkinsons Disease Drugs Consumption by Regions
        • 4.1.2 Global Parkinsons Disease Drugs Value by Regions
      • 4.2 Americas Parkinsons Disease Drugs Consumption Growth
      • 4.3 APAC Parkinsons Disease Drugs Consumption Growth
      • 4.4 Europe Parkinsons Disease Drugs Consumption Growth
      • 4.5 Middle East & Africa Parkinsons Disease Drugs Consumption Growth

      5 Americas

      • 5.1 Americas Parkinsons Disease Drugs Consumption by Countries
        • 5.1.1 Americas Parkinsons Disease Drugs Consumption by Countries (2013-2018)
        • 5.1.2 Americas Parkinsons Disease Drugs Value by Countries (2013-2018)
      • 5.2 Americas Parkinsons Disease Drugs Consumption by Type
      • 5.3 Americas Parkinsons Disease Drugs Consumption by Application
      • 5.4 United States
      • 5.5 Canada
      • 5.6 Mexico
      • 5.7 Key Economic Indicators of Few Americas Countries

      6 APAC

      • 6.1 APAC Parkinsons Disease Drugs Consumption by Countries
        • 6.1.1 APAC Parkinsons Disease Drugs Consumption by Countries (2013-2018)
        • 6.1.2 APAC Parkinsons Disease Drugs Value by Countries (2013-2018)
      • 6.2 APAC Parkinsons Disease Drugs Consumption by Type
      • 6.3 APAC Parkinsons Disease Drugs Consumption by Application
      • 6.4 China
      • 6.5 Japan
      • 6.6 Korea
      • 6.7 Southeast Asia
      • 6.8 India
      • 6.9 Australia
      • 6.10 Key Economic Indicators of Few APAC Countries

      7 Europe

      • 7.1 Europe Parkinsons Disease Drugs by Countries
        • 7.1.1 Europe Parkinsons Disease Drugs Consumption by Countries (2013-2018)
        • 7.1.2 Europe Parkinsons Disease Drugs Value by Countries (2013-2018)
      • 7.2 Europe Parkinsons Disease Drugs Consumption by Type
      • 7.3 Europe Parkinsons Disease Drugs Consumption by Application
      • 7.4 Germany
      • 7.5 France
      • 7.6 UK
      • 7.7 Italy
      • 7.8 Russia
      • 7.9 Spain
      • 7.10 Key Economic Indicators of Few Europe Countries

      8 Middle East & Africa

      • 8.1 Middle East & Africa Parkinsons Disease Drugs by Countries
        • 8.1.1 Middle East & Africa Parkinsons Disease Drugs Consumption by Countries (2013-2018)
        • 8.1.2 Middle East & Africa Parkinsons Disease Drugs Value by Countries (2013-2018)
      • 8.2 Middle East & Africa Parkinsons Disease Drugs Consumption by Type
      • 8.3 Middle East & Africa Parkinsons Disease Drugs Consumption by Application
      • 8.4 Egypt
      • 8.5 South Africa
      • 8.6 Israel
      • 8.7 Turkey
      • 8.8 GCC Countries

      9 Market Drivers, Challenges and Trends

      • 9.1 Market Drivers and Impact
        • 9.1.1 Growing Demand from Key Regions
        • 9.1.2 Growing Demand from Key Applications and Potential Industries
      • 9.2 Market Challenges and Impact
      • 9.3 Market Trends

      10 Marketing, Distributors and Customer

      • 10.1 Sales Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.2 Parkinsons Disease Drugs Distributors
      • 10.3 Parkinsons Disease Drugs Customer

      11 Global Parkinsons Disease Drugs Market Forecast

      • 11.1 Global Parkinsons Disease Drugs Consumption Forecast (2018-2023)
      • 11.2 Global Parkinsons Disease Drugs Forecast by Regions
        • 11.2.1 Global Parkinsons Disease Drugs Forecast by Regions (2018-2023)
        • 11.2.2 Global Parkinsons Disease Drugs Value Forecast by Regions (2018-2023)
        • 11.2.3 Americas Consumption Forecast
        • 11.2.4 APAC Consumption Forecast
        • 11.2.5 Europe Consumption Forecast
        • 11.2.6 Middle East & Africa Consumption Forecast
      • 11.3 Americas Forecast by Countries
        • 11.3.1 United States Market Forecast
        • 11.3.2 Canada Market Forecast
        • 11.3.3 Mexico Market Forecast
        • 11.3.4 Brazil Market Forecast
      • 11.4 APAC Forecast by Countries
        • 11.4.1 China Market Forecast
        • 11.4.2 Japan Market Forecast
        • 11.4.3 Korea Market Forecast
        • 11.4.4 Southeast Asia Market Forecast
        • 11.4.5 India Market Forecast
        • 11.4.6 Australia Market Forecast
      • 11.5 Europe Forecast by Countries
        • 11.5.1 Germany Market Forecast
        • 11.5.2 France Market Forecast
        • 11.5.3 UK Market Forecast
        • 11.5.4 Italy Market Forecast
        • 11.5.5 Russia Market Forecast
        • 11.5.6 Spain Market Forecast
      • 11.6 Middle East & Africa Forecast by Countries
        • 11.6.1 Egypt Market Forecast
        • 11.6.2 South Africa Market Forecast
        • 11.6.3 Israel Market Forecast
        • 11.6.4 Turkey Market Forecast
        • 11.6.5 GCC Countries Market Forecast
      • 11.7 Global Parkinsons Disease Drugs Forecast by Type
      • 11.8 Global Parkinsons Disease Drugs Forecast by Application

      12 Key Players Analysis

      • 12.1 Johnson & Johnson
        • 12.1.1 Company Details
        • 12.1.2 Parkinsons Disease Drugs Product Offered
        • 12.1.3 Johnson & Johnson Parkinsons Disease Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.1.4 Main Business Overview
        • 12.1.5 Johnson & Johnson News
      • 12.2 Gilead Sciences
        • 12.2.1 Company Details
        • 12.2.2 Parkinsons Disease Drugs Product Offered
        • 12.2.3 Gilead Sciences Parkinsons Disease Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.2.4 Main Business Overview
        • 12.2.5 Gilead Sciences News
      • 12.3 Pacira
        • 12.3.1 Company Details
        • 12.3.2 Parkinsons Disease Drugs Product Offered
        • 12.3.3 Pacira Parkinsons Disease Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.3.4 Main Business Overview
        • 12.3.5 Pacira News
      • 12.4 Sun Pharmaceutical
        • 12.4.1 Company Details
        • 12.4.2 Parkinsons Disease Drugs Product Offered
        • 12.4.3 Sun Pharmaceutical Parkinsons Disease Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.4.4 Main Business Overview
        • 12.4.5 Sun Pharmaceutical News
      • 12.5 Luye Pharma
        • 12.5.1 Company Details
        • 12.5.2 Parkinsons Disease Drugs Product Offered
        • 12.5.3 Luye Pharma Parkinsons Disease Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.5.4 Main Business Overview
        • 12.5.5 Luye Pharma News
      • 12.6 Sigma-Tau Group
        • 12.6.1 Company Details
        • 12.6.2 Parkinsons Disease Drugs Product Offered
        • 12.6.3 Sigma-Tau Group Parkinsons Disease Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.6.4 Main Business Overview
        • 12.6.5 Sigma-Tau Group News
      • 12.7 Fudan-Zhangjiang
        • 12.7.1 Company Details
        • 12.7.2 Parkinsons Disease Drugs Product Offered
        • 12.7.3 Fudan-Zhangjiang Parkinsons Disease Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.7.4 Main Business Overview
        • 12.7.5 Fudan-Zhangjiang News
      • 12.8 Teva Pharmaceutical
        • 12.8.1 Company Details
        • 12.8.2 Parkinsons Disease Drugs Product Offered
        • 12.8.3 Teva Pharmaceutical Parkinsons Disease Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.8.4 Main Business Overview
        • 12.8.5 Teva Pharmaceutical News
      • 12.9 CSPC
        • 12.9.1 Company Details
        • 12.9.2 Parkinsons Disease Drugs Product Offered
        • 12.9.3 CSPC Parkinsons Disease Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.9.4 Main Business Overview
        • 12.9.5 CSPC News
      • 12.10 Novartis
        • 12.10.1 Company Details
        • 12.10.2 Parkinsons Disease Drugs Product Offered
        • 12.10.3 Novartis Parkinsons Disease Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.10.4 Main Business Overview
        • 12.10.5 Novartis News
      • 12.11 Kingond Pharm

      13 Research Findings and Conclusion

      In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Parkinsons Disease Drugs market for 2018-2023.

      Parkinson's disease (PD) is a long-term degenerative disorder of the central nervous system that mainly affects the motor system.The symptoms generally come on slowly over time.Early in the disease, the most obvious are shaking, rigidity, slowness of movement, and difficulty with walking.Thinking and behavioral problems may also occur.Dementia becomes common in the advanced stages of the disease.Depression and anxiety are also common, occurring in more than a third of people with PD.Other symptoms include sensory, sleep, and emotional problems.The main motor symptoms are collectively called "parkinsonism", or a "parkinsonian syndrome"
      The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
      This report analyzes the worldwide markets for Parkinsons Disease Drugs in US$ by following Product Segments.: Clinical, Experiment
      Company profiles are primarily based on public domain information including company
      Johnson & Johnson
      Gilead Sciences
      Pacira
      Sun Pharmaceutical
      Luye Pharma
      Sigma-Tau Group
      Fudan-Zhangjiang
      Teva Pharmaceutical
      CSPC
      Novartis
      Kingond Pharm

      Over the next five years, LPI(LP Information) projects that Parkinsons Disease Drugs will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.

      This report presents a comprehensive overview, market shares, and growth opportunities of Parkinsons Disease Drugs market by product type, application, key manufacturers and key regions.

      To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:

      Segmentation by product type:
      Clinical
      Experiment
      Segmentation by application:
      Treament
      Prevention

      This report also splits the market by region:
      Americas
      United States
      Canada
      Mexico
      Brazil
      APAC
      China
      Japan
      Korea
      Southeast Asia
      India
      Australia
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Middle East & Africa
      Egypt
      South Africa
      Israel
      Turkey
      GCC Countries

      The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
      Johnson & Johnson
      Gilead Sciences
      Pacira
      Sun Pharmaceutical
      Luye Pharma
      Sigma-Tau Group
      Fudan-Zhangjiang
      Teva Pharmaceutical
      CSPC
      Novartis
      Kingond Pharm

      In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

      Research objectives
      To study and analyze the global Parkinsons Disease Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
      To understand the structure of Parkinsons Disease Drugs market by identifying its various subsegments.
      Focuses on the key global Parkinsons Disease Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
      To analyze the Parkinsons Disease Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      To project the consumption of Parkinsons Disease Drugs submarkets, with respect to key regions (along with their respective key countries).
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
      To strategically profile the key players and comprehensively analyze their growth strategies.


      Summary:
      Get latest Market Research Reports on Parkinsons Disease Drugs . Industry analysis & Market Report on Parkinsons Disease Drugs is a syndicated market report, published as 2018-2023 Global Parkinsons Disease Drugs Consumption Market Report. It is complete Research Study and Industry Analysis of Parkinsons Disease Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $4,660.00
      $6,990.00
      $9,320.00
      3,734.27
      5,601.40
      7,468.54
      4,154.98
      6,232.47
      8,309.96
      502,627.60
      753,941.40
      1,005,255.20
      321,057.22
      481,585.84
      642,114.45
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report